

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

10530,499

Filing Date

April 6, 2005

First Named Inventor

Page

Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

100831-1P US

**ENCLOSURES (Check all that apply)**☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a  
Provisional Application☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD☐

After Allowance Communication to TC

☐Appeal Communication to Board  
of Appeals and Interferences☐Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☐Other Enclosure(s) (please identify  
below):

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

AstraZeneca

Signature

Printed name

Jianzhong Shen

Date

May 20, 2005

Reg. No.

48,076

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Liz Ashton

Date

May 20, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No : 10/530,499 PCT Application No.: PCT/SE03/01604  
Applicant : Pagé et al. PCT Filing Date: October 15, 2003  
National Phase Fld (371): April 6, 2005  
TC/A.U. : Unknown  
Examiner : Unknown  
Docket No. : 100831-1P US  
Customer No. : 22466  
Title : Novel Compounds

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: May 20, 2005



Signature



Typed or printed name of person signing certificate

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached forms PTO/SB/08A and SB/08B. Applicants also wish to make the Examiner aware of co-pending applications: 10/474,549, a PCT national phase filed on April 18, 2002. Copies of the cited references, excluding the U.S. patent, are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and SB/08B forms.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed within three months of the filing date of this application, and before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,

  
\_\_\_\_\_  
Jianzhong Shen  
Reg. No. 48,076  
302-886-8854

Dated: May 20, 2005

Enclosures: Form PTO/SB/08A  
Form PCT/SB/08B  
References (14)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 2 of 2

**Complete if Known**

Application Number	10/530,499
Filing Date	April 6, 2005
First Named Inventor	Page
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	100831-1P US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		STN International, file CAPLUS, CAPLUS accession no. 1973-87, document no. 78:87, Paglietti G. et al, "Dialkylaminoalkylbenzimidazoles of pharmacological interest", & Studi Sassaesi, Sezione 2: Archivio Bimestrale di Scienze Mediche e Naturali (1971), 49(5-6), 192-203	<input type="checkbox"/>
		SEKI, T. et al., "2-Benzimidazolethiol derivatives... -5-substituted, benzimidazole", Chem. Abstracts, 1969, pg. 445, Vol. 71, No. 13, THE ABSTRACT, No. 61291h, Yakugaku Zasshi, 1969, 89 (5), 617-626	<input type="checkbox"/>
		PAGLIETTI, G. et al., "Dialkylaminoalkylbenzimidazoles of pharmacological interest III", Chem. Abstracts, 1972, pg. 479, Vol. 77, No. 7, THE ABSTRACT, No. 48338h, Farmaco, Ed. Sci. 1972, 27 (4), 333-342	<input type="checkbox"/>
		LECOLIER, S. et al., "New benzimidazoles with morphine activity", Chim. Ther., 1967, pgs 16-24, Vol. 2, No. 1	<input checked="" type="checkbox"/>
		BURKE, T. et al., "Probes for Narcotic Receptor Mediated Phenomena. 7. <sup>1</sup> Synthesis and Pharmacological Properties of Irreversible Ligands Specific for $\mu$ or $\delta$ Opiate Receptors", J. Med. Chem., 1984, pgs. 1570-1574, Vol. 27	<input type="checkbox"/>
		SMITH, J. et al., "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylamino benzimidazoles", J. Comb. Chem., 1999, pgs. 368-370, Vol. 1	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature	/Niloofer Rahmani/		Date Considered 04/08/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for Form 1449/PTO

(Use as many sheets as necessary)

**SHEET 1 of 2**

**Complete if Known**

Application Number	10/530,499
Filing Date	April 6, 2005
First Named Inventor	Page
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	100831-1P US

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 97/19063	05-29-1997	Sanofi		<input type="checkbox"/>
		WO 00/46209	08-10-2000	Sanofi-Synthelabo		<input type="checkbox"/>
		WO 02/36590	05-10-2002	Amrad Operations Pty Ltd		<input type="checkbox"/>
		WO 02/060447	08-08-2002	University of Connecticut		<input type="checkbox"/>
		WO 02/085866	10-31-2002	AstraZeneca AB		<input type="checkbox"/>
		WO 2004/035548	04-29-2004	AstraZeneca AB		<input type="checkbox"/>
		EP 0445781	09-11-1991	Sterling Drug Inc.		<input type="checkbox"/>
		FR 1481049	05-19-1967	Serge Lécoulér		<input checked="" type="checkbox"/>
Examiner Signature	/Niloufar Rahmani/			Date Considered	04/08/2008	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the issuance of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Transmittal instructions: Information is required under 37 CFR 1.97 and 1.98. The information is requested to obtain or retain a benefit by the public which is to file (and if the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/